Thank you for sharing!

Your article was successfully shared with the contacts you provided.

As The Am Law Litigation Daily reported last week, AstraZeneca received some bad news on Wednesday from the 1st Circuit, which affirmed a lower court’s ruling in a test case in the multi-district proceeding over drug companies’ alleged manipulation of average wholesale prices for drugs. Although the 1st Circuit ruling spells trouble for the company in the MDL, plaintiffs attorney Steven Berman of Hagens Berman told us that it may not have an impact on the cases brought against AstraZeneca by various state and local governments, which are using slightly different theories to show that Big Pharma manipulated the published prices of their drugs.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.